Jul 2 |
Vertex’s cystic fibrosis drug gets FDA priority review
|
Jul 2 |
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis
|
Jul 1 |
Vertex to Announce Second Quarter 2024 Financial Results on August 1
|
Jul 1 |
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
|
Jun 29 |
Insider Sale at Vertex Pharmaceuticals Inc (VRTX): EVP and CMO Carmen Bozic Sells 2,280 Shares
|
Jun 28 |
2 Superior Growth Stocks to Buy if You Have $1,000 Right Now
|
Jun 28 |
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
|
Jun 28 |
2 Healthcare Stocks That Are Screaming Buys in June
|
Jun 27 |
Vertex (VRTX) Rises 16.5% YTD: Time to Bet On the Stock?
|
Jun 27 |
Is CRISPR Therapeutics Stock a Buy? One Analyst Thinks the Biotech Is "Very Undervalued."
|